HanAll Biopharma
The author is an analyst for NH Investment & Securities. He can be reached at seungyeon.han@nhqv.com -- Ed.
We expect HanAll Biopharma to showcase a new royalty revenue business model within the Korea biotech industry. The firm is to generate large-scale global royalty revenue by developing next-generation best-in-class candidates for autoimmune diseases which have the potential to become new blockbuster drugs. We spot a clearly underestimated EV level compared to that for current global partner Immunovant.
Seungyeon Han
pr@businesskorea.co.kr